Organisation paid for research Program year 2025 Source: CMS Open Payments

Marshfield Clinic Marshfield Center

Neither a doctor nor a teaching hospital

Research payments

$193,827

120 payments

Through program year 2025, Marshfield Clinic Marshfield Center is reported as receiving $193,827 in research payments, across 120 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$54,014	4
2024	Research	$50,964	56
2021	Research	$40,639	32
2020	Research	$48,210	28

Breakdown

Who paid Research payments · program years 2020–2025

Retrophin, Inc. $123,812 110 payments
Celgene Corporation $35,800 1 payment
E.R. Squibb & Sons, L.L.C. $20,174 4 payments
Novo Nordisk AS $13,255 3 payments
AstraZeneca Pharmaceuticals LP $786 2 payments

Studies the money was for Research payments · program years 2020–2025

A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). $54,014 4 payments
021Fsgs16010 $51,073 46 payments
021Igan17001 $40,881 43 payments
Duet $31,859 21 payments
Nn9536-4451 $13,255 3 payments
Phase III RRMM: 480Kd vs Kd (SUCCESSOR 2) - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR R $1,960 1 payment
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) $786 2 payments

What the money was spent on Research payments · program years 2020–2025

Other $74,808 55 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.